Notably, the FDA recently granted orphan drug designation to KT-253, a novel MDM2 degrader, for the treatment of acute myeloid leukemia (AML), underscoring the clinical potential of this innovative strategy (Wang W. et al., 2024). The gene discussed is MDM2; the disease is acute myeloid leukemia.